Inhibition of aggregate formation as therapeutic target in protein misfolding diseases: Effect of tetracycline and trehalose

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 12, 2010, Pages 1311-1321

  Sirangelo, Ivana ^a,b   Irace, Gaetano ^a,b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

Author keywords

amyloid cytotoxicity; anti amyloidogenic compounds; fibrillogenesis

Indexed keywords

AMYLOID; COLLAGEN FIBRIL; TETRACYCLINE; TREHALOSE;

APOPTOSIS; CELL DEGENERATION; CELL MIGRATION; CYTOTOXICITY; GENE MUTATION; HUNTINGTON CHOREA; NONHUMAN; PROTEIN AGGREGATION; PROTEIN DEFECT; PROTEIN FOLDING; PROTEIN POLYMERIZATION; REVIEW;

AMYLOID; AMYLOIDOGENIC PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; NEURODEGENERATIVE DISEASES; PROTEIN SYNTHESIS INHIBITORS; PROTEINS; PROTEOSTASIS DEFICIENCIES; TETRACYCLINE; TREHALOSE;

EID: 78249258414     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2010.531012     Document Type: Review

References (101)

1. Carrell RW, Lomas DA. Conformational disease. Lancet 1997;350:134-8
2. Westermark P, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature-2002. Amyloid 2002;9:197-200
3. Buxbaum JN, Tagoe CE. The genetics of the amyloidoses. Annu Rev Med 2000;51:543-69
4. Makin OS, Serpell LC. Examining the structure of the mature amyloid fibril. Biochem Soc Trans 2002;30:521-5
5. Sipe JD, Cohen AS. Review: history of the amyloid fibril. J Struct Biol 2000;130:88-98
6. Nelson R, Sawaya MR, Balbirnie M, et al. Structure of the cross-beta spine of amyloid fibrils. Nature 2005;435:773-8
7. DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997;277:1990-3
8. Tsuchiya K, Shintani S, Nakabayashi H, et al. Familial amyotrophic lateral sclerosis with onset in bulbar sign, benign clinical course, and Bunina bodies: a clinical, genetic, and pathological study of a Japanese family. Acta Neuropathol (Berl) 2000;100:603-7
9. Spillantini MG, Schmidt ML, Lee VM, et al. alpha-Synuclein in lewy bodies. Nature 1997;388:839-40
10. Parmar JS, Lomas DA. alpha-1-antitrypsin deficiency, the serpinopathies and conformational disease. J R Coll Physicians Lond 2000;34:295-300
11. Guijarro JI, Sunde M, Jones JA, et al. Amyloid fibril formation by an SH3 domain. Proc Natl Acad Sci USA 1998;95:4224-8
12. Litvinovich SV, Brew SA, Aota S, et al. Formation of amyloid like fibrils by self association of a partially unfolded fibronectin type III module. J Mol Biol 1998;280:245-58
13. Chiti F, Webster P, Taddei N, et al. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci USA 1999;96:3590-4
14. Fandrich M, Fletcher MA, Dobson CM. Amyloid fibrils from muscle myoglobin. Nature 2001;410:165-6
15. Sirangelo I, Malmo C, Casillo M, et al. Tryptophanyl substitution in apomyoglobin determine protein aggregation and amyloid-like fibril formation at physiological pH. J Biol Chem 2002;277:45887-91
16. Sirangelo I, Malmo C, Iannuzzi C, et al. Fibrillogenesis and cytotoxic activity of the amyloid-forming apomyoglobin mutant W7FW14F. J Biol Chem 2004;279:13183-9
17. Astbury WT, Dickinson S, Bailey K. The X-ray interpretation of the denaturation and the structure of the seed globulins. Biochem J 1935;29:2351-60
18. Eroglu B, Moskophidis D, Mivechi NF. Loss of Hsp110 leads to age-dependent Tau hyperphosphorylation and early accumulation of insoluble amyloid-beta. Mol Cell Biol 2010;30(19):4626-43
19. Nakamura T, Lipton SA. Cell death: protein misfolding and neurodegenerative diseases. Apoptosis 2009;14(4):455-68
20. Chiti F, Dobson CM. Amyloid formation by globular proteins under native conditions. Nat Chem Biol 2009;5(1):15-22
21. Roychaudhuri R, Yang M, Hoshi MM, Teplow DB. Amyloid beta-protein assembly and Alzheimer disease. J Biol Chem 2009;284(8):4749-53
22. Kelly JW. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 1998;8:101-6
23. Harper JD, Lansbury PT Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the timedependent solubility of amyloid proteins. Annu Rev Biochem 1997;66:385-407
24. Lashuel HA, Petre BM, Wall J, et al. alpha-Synuclein, especially the Parkinson's disease-associated mutants, forms porelike annular and tubular protofibrils. J Mol Biol 2002;322:1089-102
25. Poirier MA, Li H, Macosko J, et al. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrillization. J Biol Chem 2002;277:41032-7
26. Quintas A, Vaz DC, Cardoso I, et al. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem 2001;276:27202-13
27. Serpell LC, Sunde M, Blake CC. The molecular basis of amyloidosis. Cell Mol Life Sci 1997;53:871-87
28. Necula M, Kayed R, Milton S, Glabe C. Small molecules inhibitors distinguish between amyloid beta oligomerization and fibrillization pathways. J Biol Chem 2007;28:10311-24
29. Stefani M. Protein folding and misfolding on surfaces Int J Mol Sci 2008;9:2515-2542
30. Uversky VN. Mysterious oligomerization of the amyloidogenic proteins. FEBS J 2010;277(14):2940-53
31. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996;55:259-72
32. Thomas PJ, Qu BH, Pedersen PL. Defective protein folding as a basis of human disease. Trends Biochem Sci 1995;20:456-9
33. Stefani M, Dobson CM. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med 2003;81:678-99
34. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416:535-9
35. Kayed R, Head E, Thomson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003;300:486-9
36. Bucciantini M, Giannoni E, Chiti F, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding disease. Nature 2002;416:507-11
37. Walsh DM, Selkoe DJ. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 2004;11:213-28
38. Lashuel HA, Hartley D, Petre BM, et al. Neurogenerative disease: amyloid pores from pathogenic mutations. Nature 2002;418:291
39. Dickson DW. Correlation of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 1995;16:285-98
40. Hartley D, Walsh DM, Ye CP, et al. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 1999;19:8876-84
41. Bucciantini M, Calloni G, Chiti F, et al. Prefibrillar amyloid protein aggregates share common features of cytotoxicity. J Biol Chem 2004;279:31374-82
42. Lin H, Bhatia R, Lal R. Amyloid beta protein forms ion channels: implications for Alzheimer's diseases pathophysiology. FASEB J 2001;15:2433-44
43. Hirakura Y, Carreras I, Sipe JD, Kagan BL. Channel formation by serum amyloid A: a potential mechanism for amyloid pathogenesis and host defence. Amyloid 2002;9:13-23
44. Svanborg C, Agerstam H, Aronson A, et al. HAMLET kills tumor cells by an apoptosis-like mechanism-cellular, molecular, and therapeutic aspects. Adv Cancer Res 2003;88:1-29
45. Leliveld S, Noteborn MH, Abrahams JP. Prevalent conformations and subunit exchange in the biologically active apoptin protein multimer. Eur J Biochem 2003;270:3619-27
46. Zhang YH, Leliveld SR, Kooistra K, et al. Recombinant Apoptin multimers kill tumor cells but are nontoxic and epitope-shielded in a normal-cell-specific fashion. Exp Cell Res 2003;289:36-46
47. Hotze EM, Heuck AP, Czajkowsky DM, et al. Monomer-monomer interactions drive the prepore to pore conversion of a beta-barrel-forming cholesterol-dependent cytolysin. J Biol Chem 2002;277:11597-605
48. Valeva A, Schnabell R, Valev I, et al. Membrane insertion of the heptameric staphylococcal alpha-toxin pore. A domino-like structural transition that is allosterically modulated by the target cell membrane. J Biol Chem 2001;276:14835-41
49. Miyata S, Matsushita O, Minami J, et al. Cleavage of a C-terminal peptide is essential for heptamerization of Clostridium perfringens e-toxin in the synaptosomal membrane. J Biol Chem 2001;276:13778-83
50. Hirakura Y, Kagan BL. Pore formation by beta-2-microglobulin: a mechanism for the pathogenesis of dialysis associated amyloidosis. Amyloid 2001;8:94-100
51. Wang L, Lashuel HA, Walz T, Colon W. Murine apolipoprotein serum amyloid A in solution forms a hexamer containing a central channel. Proc Natl Acad Sci USA 2002;99:15947-52
52. Kourie JI, Henry CL. Ion channel formation and membrane-linked pathologies of misfolded hydrophobic proteins: the role of dangerous unchaperoned molecules. Clin Exp Pharmacol Physiol 2002;29:741-53
53. Kagan B, Azimov R, Azimova R. Amyloid peptide channels. J Membr Biol 2004;202:1-10
54. Engel MF. Membrane permeabilization by islet amyloid polypeptide. Chem Phys Lipids 2009;160(1):1-10
55. Arispe N, Doh M. Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease AbetaP (1-40) and (1-42) peptides. FASEB J 2002;16:1526-36
56. Yip CM, Elton EA, Darabie AA, et al. Cholesterol, a modulator of membrane-associated Abeta-fibrillogenesis and neurotoxicity. J Mol Biol 2001;311:723-34
57. Merlini G, Ascari E, Amboldi N, et al. Interaction of the antjracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci USA 1995;92:2959-63
58. Heiser V, Scherzinger E, et al. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc Natl Acad Sci USA 2000;97:6739-44
59. Forloni G, Colombo L, Girola L, et al. Antiamyloidogenicactivity of tetracyclines: studies in vitro. FEBS Lett 2001;487:404-7
60. Howlett DR, Perry AE, Godfrey F, et al. Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans. Biochem J 1999;340:283-9
61. Sebastiano MP, Merlini G, Saraiva MJ, Damas AM. The molecular interaction of 4′-iodo-4′-deoxydoxorubicin with Leu-55Pro transthyretin 'amyloid-like' oligomer leading to disaggregation. Biochem J 2000;351:273-9
62. Cardoso I, Merlini G, Saraiva MJ. 4′-iodo-4′-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producine noncytotoxic species: screening for TTR fibril disrupters. FASEB J 2003;17:803-9
63. Li J, Zhu M, Manning-Bog AB, et al. Dopamine and L-dopa disaggregate amyloid fibrils: implication for Parkinson's and Alzheimer's disease. FASEB J 2004;18:962-4
64. Findeis MA. Approaches to discovery and characterization of inhibitors of amyloid beta-peptide polymerization. Biochim Biophys Acta 2000;1502:76-84
65. Cashman NR, Caughey B. Prion diseases-close to effective therapy? Nat Rev Drug Discov 2004;3:874-84
66. Heiser V, Engemann S, Brocker W, et al. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Proc Natl Acad Sci USA 2002;99:16400-6
67. Bendeck MP, Conte M, Zhang M, et al. Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am J Pathol 2002;160:1089-95
68. Forloni G, Iussich S, Awan T, et al. Tetracyclines affect prion infectivity. Proc Natl Acad Sci USA 2002:99 (16):10849-54
69. Tagliavini F, Forloni G, Colombo L, et al. Tetracicline affects abnormal properties of synthetic PrP peptides and PrPSc in vitro. J Mol Biol 2000;300:1309-22
70. Malmo C, Vilasi S, Iannuzzi C, et al. Tetracycline inhibits W7FW14F apomyoglobin fibril extension and keeps the amyloid protein in a pre-fibrillar, highly cytotoxic state. FASEB J 2006;20(2):346-7
71. Iannuzzi C, Vilasi S, Portaccio M, et al. Heme binding inhibits the fibrillization of amyloidogenic apomyoglobin and determines lack of aggregate cytotoxicity. Protein Sci 2007;16:507-16
72. Vilasi S, Dosi R, Iannuzzi C, et al. Kinetics of amyloid aggregation of mammal apomyoglobins and correlation with their amino acid sequences. FEBS Lett 2006;580:1681-4
73. Singer MA, Lindquist S. Multiple effects of trehalose on protein folding in vitro and in vivo. Mol Cell 1998;1:639-48
74. Xie G, Timasheff SN. The thermodynamic mechanism of protein stabilization by trehalose. Biophys Chem 1997;64:25-43
75. Chen L, Cabrita G J M, Otzen DE, Melo EP. Stabilization of the ribosomal protein S6 by trehalose is counterbalanced by the formation of a putative off-pathway species. J Mol Biol 2005;351:402-16
76. Colaco C, Sen S, Thangavelu M, et al. Extraordinary stability of enzymes dried in trehalose: simplified molecular biology. Biotechnology 1992;10(9):1007-11
77. Crowe JH, Tablin F, Wolkers WF, et al. Stabilization of membranes in human platelets freeze-dried with trehalose. Chem Phys Lipids 2003;122(1-2): 41-52 (Pubitemid 36207511)
78. Benaroudj N, Lee DH, Goldberg AL. Trehalose accumulation during cellular stress protects cells and cellular proteins from damage by oxygen radicals. J Biol Chem 2001;276:24261-7
79. Jain NK, Roy I. Effect of trehalose on protein structure. Protein Sci 2009;18(1):24-36
80. Tanaka M, Makida Y, Niu S, et al. Trehalose alleviates poly-glutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 2004;10:148-54
81. Tanaka M, Makida Y, Nukina N. A novel therapeutic strategy for poly-glutamine diseases by stabilizing aggregation-prone proteins with small molecules. J Mol Med 2005;83:343-52
82. Liu R, Barkhordarian H, Emadi S, et al. Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42. Neurobiol Dis 2005;20:74-81
83. Vilasi S, Iannuzzi C, Portaccio M, et al. Effect of trehalose on W7FW14F apomyoglobin and insulin fibrillization: new insight into inhibition activity. Biochemistry 2008;47:1789-96
84. Beranger F, Crozet C, Goldsborough A, Lehmann S. Trehalose impairs aggregation of PrPSC molecules and protects prion-infected cells against oxidative damage. Biochem Biophys Res Commun 2008;334:44-8
85. Nielsen L, Khurana R, Coats A, et al. Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry 2001;40:6036-46
86. Melo EP, Faria TQ, Martins LO, et al. Cutinase unfolding and stabilization by trehalose and mannosylglycerate. Proteins 2001;42:542-52
87. Gekko K, Timasheff SN. Mechanism of protein stabilization by glycerol: preferential hydration in glycerol-water mixtures. Biochemistry 1981;20:4667-76
88. Arakawa T, Timasheff SN. Stabilization of protein structure by sugars. Biochemistry 1982;21:6536-44
89. Liu FF, Ji L, Dong XY, Sun Y. Molecular insight into the inhibition effect of trehalose on the nucleation and elongation of amyloid beta-peptide oligomers. J Phys Chem B 2009;113(32):11320-9
90. Belton PS, Gil AM. IR and Raman spectroscopic studies of the interaction of trehalose with hen egg white lysozyme. Biopolymers 1994;34:957-61
91. Lins RD, Pereira CS, Hunenberger PH. Trehalose-protein interaction in aqueous solution. Proteins 2004;55:177-86
92. Bellesia G, Shea JE. Diversity of kinetic pathways in amyloid fibril formation. J Chem Phys 2009;131(11):111102
93. Wang MS, Boddapati S, Sierks MR. Antifibrillizing agents catalyze the formation of unstable intermediate aggregates of beta-amyloid. Biotechnol Prog 2010;26(4):1172-9
94. Ehrnhoefer DE, Bieschke J, Boeddrich A, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 2008;15(6):558-66
95. Conlin LK, Nelson H C M. The natural osmolyte trehalose is a positive regulator of the heat-induced activity of yeast heat shock transcription factor. Mol Cell Biol 2007;27(4):1505-15
96. Sarkar S, Davies JE, Huang Z, et al. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem 2007;282:5641-52
97. Aguib Y, Heiseke A, Gilch S, et al. Autophagy induction by trehalose counteracts cellular prion infection. Autophagy 2009;5(3):361-9
98. Elbein AD, Pan TY, Pastuszak I, Carroll D. New insights on trehalose: a multifunctional molecule. Glycobiology 2003;13(4):7-27
99. Oku K, Kurose M, Kubota M, et al. Combined NMR and quantum chemical studies on the interaction between trehalose and dienes relevant to the antioxidant function of trehalose. J Phys Chem B 2005;109(7):3032-40
100. Nguyen HP, Bonin M, Stephan M, et al. Trehalose treatment restores calcium homeostasis in transgenic rat model of Huntington's disease [abstract 48]. Proceedings of neurodegenerative diseases: molecular mechanisms in a functional genomics framework; 6-9 September 2006; Max Delbrueck Center, Berlin-Buch
101. De Bona P, Giuffrida ML, Caraci F, et al. Design and synthesis of new trehalose-conjugated pentapeptides as inhibitors of Abeta (1-42) fibrillogenesis and toxicity. J Pept Sci 2009;15(3):220-8